Perron Institute research areas including multiple sclerosis, brain plasticity, genomic medicine, motor neurone disease and Parkinson’s have received continued funding from MSWA.
The Institute is one of the recipients of the substantial contribution of $5 million for the 2022/23 financial year announced by MSWA CEO Melanie Kiely.
“I am delighted to continue our funding of neurological research, including Western Australian research projects which we believe will lead to finding the cause, better treatments, and hopefully one day a cure for many neurological conditions,” she said.
“We truly can’t thank our supporters enough for continuing to trust us to support people with neurological conditions and fund vital research not only here in WA, but nationally and internationally too.”
Areas of support for this funding round are: Demyelinating Diseases Research (including multiple sclerosis) led by Professor Allan Kermode (Perron Institute and CMMIT (Centre for Molecular Medicine and Innovative Therapeutics), Murdoch University), MS Base registry led by Dr Marzena Fabis-Pedrini (Perron Institute and CMMIT), Neuroplasticity Research led by Associate Professor Jennifer Rodger (UWA and Perron Institute), TONiC (Trajectories of Outcome in Neurological Conditions) led by Professor Sulev Koks (Perron Institute and CMMIT), Gut microbiome in Parkinson’s led by Dr Luke Whiley (Perron Institute and CMMIT), Neurodegenerative Genomic Medicine research led by Professor Sulev Koks and Anthony Akkari (Perron Institute and CMMIT).
Perron Institute CEO Steve Arnott said he is grateful to receive further financial support from MSWA.
“Continued funding from MSWA is significant as it allows our researchers to pursue important research in areas of unmet need,” he said.
Over the past decade, MSWA has contributed over $34 million to fund research into finding the cause, better treatments and a cure for MS and other neurological conditions.